title: Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor.
abstract: BACKGROUND
  Vilazodone is the latest US Food and Drug Administration approved antidepressant agent available in the USA. Its putative mechanism of antidepressant action enhances the release of serotonin across the brain's serotonergic pathways specifically by inhibiting the serotonin transporter, similar to a selective serotonin reuptake inhibitor (SSRI), and simultaneously stimulating serotonin-1a receptors via partial agonism, similar to the anxiolytic bus-pirone. This combined activity in the single vilazodone agent has been termed by the authors as being a serotonin partial agonist and reuptake inhibitor or (SPARI).
  
  
  METHODS
  A MEDLINE and Internet search was conducted and the resultant preclinical and clinical evidence was reviewed. The authors attempt to review laboratory data, animal model data and human trial data to develop a translational theory on the mechanism of antidepressant action of this agent and also its adverse effect potential.
  
  
  RESULTS
  Randomized, controlled empirical data for vilazodone have gained it approval for treating major depressive disorder. It combines two well known pharmacodynamic mechanisms of serotonergic action into a novel agent. Although no head-to-head studies against other antidepressants have been published, the efficacy data for vilazodone appear comparable to other known antidepressants, with similar gastrointestinal side effects to SSRI or serotonin norepinephrine reuptake inhibitor (SNRI) antidepressants, but possibly with a lower incidence of sexual side effects and weight gain.
  
  
  CONCLUSIONS
  Vilazodone will lend itself to the current armamentarium in the treatment of major depressive disorder and may hold promise for patients who cannot tolerate other antide-pressants. Its unique SPARI mechanism of action could also be efficacious for patients who do not respond to SSRI or SNRI antidepressant monotherapies.
authors: SUNY Upstate Medical University, Syracuse, New York, USA.
authors: Thomas L
authors: TL
authors: Schwartz
authors: Umar A
authors: UA
authors: Siddiqui
authors: Stephen M
authors: SM
authors: Stahl
keywords: antidepressant; major depressive disorder; serotonin; vilazodone
references: Eur J Pharmacol. 2004 Nov 3;504(1-2):65-77
references: 15507223
references: J Clin Psychiatry. 2011 Apr;72(4):441-7
references: 21527122
references: Br J Pharmacol. 2000 Aug;130(7):1713-9
references: 10928979
references: Pharmacol Biochem Behav. 1990 May;36(1):203-5
references: 1971951
references: J Clin Psychiatry. 2006 May;67(5):798-806
references: 16841630
references: CNS Neurosci Ther. 2009 Summer;15(2):107-17
references: 19499624
references: CNS Spectr. 2009 Jun;14(6):299-313
references: 19668121
references: Am J Psychiatry. 2010 Mar;167(3):241-3
references: 20194484
references: J Clin Psychiatry. 1987 May;48(5):201-3
references: 2883173
references: Psychopharmacology (Berl). 2001 May;155(2):187-92
references: 11401008
references: Am J Psychiatry. 1993 Apr;150(4 Suppl):1-26
references: 8465906
references: Am J Psychiatry. 2010 Mar;167(3):281-8
references: 20008946
references: N Engl J Med. 2006 Mar 23;354(12):1243-52
references: 16554526
references: Eur J Pharmacol. 2005 Mar 7;510(1-2):49-57
references: 15740724
references: J Neurosci Methods. 1985 Aug;14(3):149-67
references: 2864480
references: Eur J Pharmacol. 2005 Jul 4;517(1-2):59-63
references: 15978574
references: Eur J Pharmacol. 1997 Mar 19;322(2-3):147-53
references: 9098681
references: Nucl Med Biol. 2000 Jul;27(5):509-13
references: 10962259
references: Pharmacol Biochem Behav. 1993 Feb;44(2):463-9
references: 8446680
references: Psychiatry (Edgmont). 2006 Jul;3(7):42-61
references: 20975817
references: J Med Chem. 2004 Sep 9;47(19):4684-92
references: 15341484
references: J Pharmacol Exp Ther. 2002 Sep;302(3):1220-7
references: 12183683
references: J Clin Psychiatry. 2009 Mar;70(3):326-33
references: 19284933
references: Am J Psychiatry. 2006 Nov;163(11):1905-17
references: 17074942
references: J Clin Psychiatry. 2009 Nov;70(11):1493-4
references: 20031093
references: CNS Spectr. 2010 Feb;15(2):79-94
references: 20414154
references: Pharmacol Biochem Behav. 2004 Jan;77(1):69-75
references: 14724043